About Telemachus Therapeutics
Telemachus Therapeutics is a pharmaceutical startup. It plans to link therapeutic research with cloud-based analysis of research data, so each result stays tied to its source and its limits. The workflow is still a plan and not a deployed service. The company names no drug candidate, target or development stage. It invites possible collaborators to send a non-confidential introduction about a scientific or research-data question.
Telemachus is a Delaware corporation incorporated in 2026. Its address is 401 Woodhaven Drive, Wexford, Pennsylvania 15090. Michael Bozik is the contact for company and partnership inquiries. He and Gregory Hebrank are the company's executive officers and directors. It does not publish unverified partner logos, affiliations or collaboration claims.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Aug 20, 2026 | Sep 2, 2026amended Oct 28, 2026 | $375,000of $1.5M target | 3 | $125K | Options, Securities on exercise, Simple Agreement for Future Equity (SAFE)Rule 506(b) | Form D/A ↗1 earlier filing |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed Telemachus Therapeutics
Telemachus Therapeutics is a pharmaceutical startup in Wexford, Pennsylvania. It was incorporated in Delaware in 2026. It plans to pair therapeutic research with cloud-based analysis of research data. So far it offers a proposed workflow for keeping that data traceable, and no clinical results.
The problem it targets
Telemachus's view is that computer analysis by itself cannot show that a therapy helps patients. Its plan is to set the biological or therapeutic question first, then name the evidence it needs and the uncertainties that matter. Only after that would a team interpret a dataset.
What the product does
The planned workflow has four steps. An intake step would keep each dataset tied to its origin, intended use and permissions. A quality step would document missing data, format and version before interpretation. An analysis step would link the settings, code versions and outputs of each run in a reviewable record. A review step would set findings next to the assumptions and uncertainty behind them. It would also name the evidence that could support the next decision.
Progress so far
The diagram on the company's website is an illustration with no live research data. The website offers no patient portal and takes no research-data uploads. The company announces no clinical result or regulatory approval, and no treatment is for sale.
We wrote this summary from public statements by Telemachus Therapeutics and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on Telemachus Therapeutics's Form D filed Oct 28, 2026.